August 18, 2025 — We have a flourishing market for new obesity drugs. But that market has a problem. New drug developers are stumbling over what to target with their drugs. The old way of looking at goals for new drugs in this space was to aim for greater weight loss. More is better – right? In a new […]
August 8, 2025 — This is a painful lesson and most of the world is very slow to take it to heart. Dealing with obesity – on almost every level – is a marathon, not a sprint. Today’s lesson is about orforglipron, an oral GLP-1 agonist in development by Lilly. This drug is a small molecule that can be […]
August 5, 2025 — A new study yesterday in Nature Medicine will surely add fuel to the fire of people who believe we can simply blame ultra-processed foods for the rise in obesity over the last four decades. The design of the study was solid – a randomized controlled crossover study. Just the kind of thing that sticklers for […]
July 21, 2025 — It’s no secret that Novo Nordisk is in something of a funk. In the last year, the value of the company has dropped by half. Its respected leader, Lars Fruergaard Jørgensen, stepped down suddenly in May. Lilly has taken the lead in the obesity market from semaglutide with its own tirzepatide, and numerous competitors are […]
July 11, 2025 — A new scientific statement from the American College of Cardiology (ACC) marks a milestone in acknowledging the importance of treating obesity in patients with heart failure. It seems that cardiologists see the light and are recognizing the importance of moving beyond diet and lifestyle advice alone. The statement concludes: “Given emerging evidence of the benefits […]
June 26, 2025 — Stepping back from the intense swirl of obesity care research at the ADA meeting just concluded, one thing stands out: People are having a very hard time following the thread of all this innovation. If you have any doubt, just scan the reports of investment analysts at the meeting. On one hand, they know they […]
June 23, 2025 — With two new publications in the New England Journal of Medicine, we are thinking that CagriSema has something to teach us about using weight loss outcomes to judge the merits of a new obesity medicine. Is more always better? Researchers presented the data from these two pivotal clinical trials on CagriSema at the ADA Scientific […]
June 19, 2025 — In drug therapy for obesity, all of the excitement about GLP-1s and now amylin analogs has focused on regulation of eating behaviors. But, in fact, this is just one part of the process for regulating metabolic function and adiposity. Until now, we have seen little success in developing safe and effective medicines that alter the […]
June 12, 2025 — It is undeniable that obesity is a complex, chronic disease. When we gather people from all over the world who understand obesity, this is the number one thing everyone can agree upon. And yet, when we sit down to talk about models for health systems delivering obesity care, it is more likely that folks who […]
June 7, 2025 — Mental health often, but not always, improves after metabolic and bariatric surgery. But new research tells us that this is not really a direct consequence of weight reduction. Instead, it seems that better mental health very likely comes from the reduction in experiences of weight stigma. In fact, Larissa McGarrity and colleagues found that the […]
